Fenwick Represents Sutro Biopharma in $110M Underwritten Offering

Fenwick represented Sutro Biopharma (Nasdaq: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), in an underwritten offering of 7,868,383 shares of its common stock at $13.98 per share. The gross proceeds from this offering were approximately $110 million. The offering included participation from new and existing investors.

Leerink Partners, TD Cowen and LifeSci Capital are acting as joint bookrunning managers for the proposed offering. More information can be obtained from the company announcement.

The Fenwick team was led by corporate partners Effie Toshav, Amanda Rose, and Ryan Mitteness and included corporate associates Adam Conway, Nikki Williams and Kennedii Brock.